Want to see ALLR full AI Analyst Report?
ALLR Stock Chart & Stats
$1.14
-$0.01(-0.99%)
At close: 4:00 PM EST
$1.14
-$0.01(-0.99%)
Day’s Range― - ―
52-Week Range$0.77 - $2.35
Previous CloseN/A
Volume542.33K
Average Volume (3M)146.33K
Market Cap
$21.16M
Enterprise Value$23.00M
Total Cash (Recent Filing)$19.81M
Total Debt (Recent Filing)$21.50M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Oct 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding15,910,724
10 Day Avg. Volume114,973
30 Day Avg. Volume146,334
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.58
Price to Sales (P/S)48.53
P/FCF Ratio-1.05
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue66.68
Enterprise Value/Gross Profit62.01
Enterprise Value/Ebitda-2.10
Forecast
1Y Price Target
$10.25Price Target Upside799.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.96
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Stenoparib DRP Patent ExclusivityA granted U.S. patent granting exclusivity to 2042 creates a durable intellectual property moat for pairing stenoparib with Allarity’s DRP test. That protection strengthens commercialization leverage, supports premium market access, and increases licensing or partner negotiation value over the long term.
Low Financial LeverageZero reported debt and positive equity reduce immediate solvency and interest-service risk, giving management structural flexibility to prioritize R&D or partner deals rather than debt repayments. This balance-sheet position supports strategic options during multi-year clinical development.
Biomarker-driven Development StrategyA focused companion-diagnostic strategy aligns with enduring precision-oncology trends: selecting responsive patients can raise trial success probabilities, speed regulatory review, and improve commercial uptake. This structural approach enhances the long-term odds for clinical and commercial value realization.
Bears Say
High Cash BurnSustained negative operating and free cash flow at double-digit millions annually creates structural runway pressure for a small company. Absent material revenue scale or lower spending, the burn rate necessitates recurrent financing and constrains long-term planning and investment choices.
Deep Operating Losses With Minimal RevenueVery low revenue relative to sizable operating losses indicates the business is far from self-sustaining. Persistent negative margins and weak top-line scale mean profits are unlikely in the near term without major clinical or commercial inflection, limiting organic capital generation.
Dependence On Equity Financing / Dilution RiskBoard-level approvals to expand equity pools and issue shares signal an expected need for external funding. Repeated reliance on equity dilutes existing holders and can compress long-term per-share value, while also reflecting limited access to non-dilutive funding sources.
Allarity Therapeutics News
ALLR FAQ
What was Allarity Therapeutics, Inc.’s price range in the past 12 months?
Allarity Therapeutics, Inc. lowest stock price was $0.77 and its highest was $2.35 in the past 12 months.
What is Allarity Therapeutics, Inc.’s market cap?
Allarity Therapeutics, Inc.’s market cap is $21.16M.
When is Allarity Therapeutics, Inc.’s upcoming earnings report date?
Allarity Therapeutics, Inc.’s upcoming earnings report date is Oct 13, 2026 which is in 103 days.
How were Allarity Therapeutics, Inc.’s earnings last quarter?
Allarity Therapeutics, Inc. released its earnings results on May 15, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.17.
Is Allarity Therapeutics, Inc. overvalued?
According to Wall Street analysts Allarity Therapeutics, Inc.’s price is currently Undervalued.
Does Allarity Therapeutics, Inc. pay dividends?
Allarity Therapeutics, Inc. does not currently pay dividends.
What is Allarity Therapeutics, Inc.’s EPS estimate?
Allarity Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Allarity Therapeutics, Inc. have?
Allarity Therapeutics, Inc. has 15,910,724 shares outstanding.
What happened to Allarity Therapeutics, Inc.’s price movement after its last earnings report?
Allarity Therapeutics, Inc. reported an EPS of -$0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.926%.
Which hedge fund is a major shareholder of Allarity Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ALLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
ALLR Stock 12 Month Forecast
Average Price Target
$10.25
▲(799.12% Upside)
Technical Analysis
Ownership Overview
7.69% Insiders
1.90% Mutual Funds
1.49% Other Institutional Investors
87.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---